GLP1R and fatty liver disease: These data indicate that while GLP-1R agonists can effectively reduce body mass—in turn reducing liver steatosis—and may have some anti-inflammatory effects by acting on a small population of liver-localized γδ T cells, they do not appear to exert anti-fibrotic effects.15